Supporting the Manufacturing of Medical Supplies in Africa: Collaboration Between Africa CDC, Partners, and Member States

Figures & Tables

TABLE.

Twenty-Two Diseases Prioritized for the Africa CDC Framework for Action

Archetype	Disease	Vaccine Exists?	African Doses Volume by 2040, million	Disability-Adjusted Life Years 2040, million
Legacy: diseases with high coverage vaccines, primarily produced by Indian players at high volumes with low unit prices.	Hepatitis B, diphtheria, tetanus, whooping cough	Yes	∼370	6
	TB	Yes	∼140	12
	Measles	Yes	∼240	2
	Yellow fever	Yes	∼50	<1
	Cholera	Yes	∼30	1
	Typhoid	Yes	∼20	1
	Meningococcus^{^a}	Yes	∼60	5
Expanding: diseases that do not yet have commoditized vaccines, where vaccines are sold at relatively higher prices with some products still in development and not yet licensed.	Human papillomavirus	Yes	∼30	4
	Pneumococcus	Yes	∼140	13
	Rotavirus	Yes	∼120	9
	COVID-19	Yes	∼710	TBD
	Malaria	Yes	∼120	20
	HIV	No	∼110	10
Outbreak: diseases that are characterized by having emerging vaccines with unpredictable demand driven by outbreaks, often with higher prices due to lower scale and urgent need.	Ebola	Yes	∼1	9
	Influenza^{^b}	Yes	∼10	1
	Chikungunya	No	∼1	<1
	Rift Valley fever	No	∼1	<1
	Lassa fever	No	∼1	<1
	Disease X^{^c}	No	N/A	N/A
	Total		2,200

Abbreviations: Africa CDC, Africa Centres for Disease Control and Prevention; N/A, not applicable; TBD, to be determined.
↵a Including key meningococcus serogroups found in Africa (A, C, W, and X).
↵b In this context, outbreak influenza.
↵c Disease X refers to a hypothetical, unknown pathogen that could emerge and result in an epidemic.